The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dose steroids and azathioprine in 72 patients subsequent to orthotopic cardiac transplantation. Overall patient sur· vival at a mean follow-up of 360 days was 92%. The number of episodes of cardiac rejection (grade 3A or greater) within 90 days of transplantation was 0.95 per patient. The actuarial freedom from rejection at 90 days was ~ 1 %. Achievement of this level of immunosuppression is comparable with that of cyclosporine-based triple-drug therapy with OKT3 immunoprophylaxis. Thirty percent of patients were tapered off all steroids, and the average steroid dose in the group who received steroids
The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dose steroids and azathioprine in 72 patients subsequent to orthotopic cardiac transplantation. Overall patient sur· vival at a mean follow-up of 360 days was 92%. The number of episodes of cardiac rejection (grade 3A or greater) within 90 days of transplantation was 0.95 per patient. The actuarial freedom from rejection at 90 days was ~ 1 %. Achievement of this level of immunosuppression is comparable with that of cyclosporine-based triple-drug therapy with OKT3 immunoprophylaxis. Thirty percent of patients were tapered off all steroids, and the average steroid dose in the group who received steroids T he potent immunosuppressive macrolide antibiotic FK 306 has undergone clinical testing at PresbyterianUni\'ersity Hospital since January 1989. The initial clinical trials were designed for liver transplant recipients with refractory rejection 11. 2), and pursuant to the dramatic and gratifying results. FK 506 was introduced as the basis of immunosuppression in kidney and liver transplant reCipients in March 1989 [3. -i), Since October 1989. in a prospective clinical trial. 7:! patients have undergone vrthl1!OplC cardiac transplantation USIn~ primarilv FK 506 .lnll low-dose sterOIds as ImmunosuppressIOn, Dramatic results were also attained In 10 patients With cardiac relectlOn .lclractorv to "Ii known com/entlonal treatment \\'hll underwent rescue therap\' With FK 506,
Material and Methods
Primary PaliCllt GrollI' Sewntv-two patients were prospecti\'ely entered into this ,Iud\' irom October 19R9 to Januarv 1992. Informed con-'l'lll W.1S obtained from each patient before transplanta-I:on tor the use of FK 506 and sterOids as the foundation ,'I Immunosuppressive therapy; 10 patients received con-\'l'ntlonal cvclosporine-based ImmunosuppreSSIOn dunn~ thi~ pCl'lod_ These 10 patients either had hemorrha~e or hl'mlldvnamlc problems that precluded the initiation 01 Flo.: 306 therapy Within 2~ hours oi transplantation or : oq:! b\' The s..lC1erv ot Thorlac SUrJl:eon!l was 8.6 mg of prednisone per day. The incidence of infection reflected the diminished necessity for steroids: seven major infections (10%) and 11 minor infections (l6%). Renal dysfunction occurred during the perioperative period in most patients in this trial. However, the incidence of hypertension was 54'7.: compared with 70'7.: during the cyclosporine era. In the study group. there were 59 men and 13 women ranging in age from 2-1 to 61 years. Eight patients (117<) required mechanical circulatory support before transpl.1n-lation in the form oi the Novacor left ventricular assist device (6). the Thoratec left "entncular assist device (1). ,md a total arhhcial he.nt (1), Six other patients aw.'lted transplantation With intraaortlc bJlloon pump support. The CJuse of cardiom\'opathv Included ischemiC (32 Resellt' Palit'II1 Grollp fhe cnteria ior the use 01 FK 506 as a "rcscue" .'gent wcrt' strictly dependent on pl.'rsistent grade 3A reJl'ctlOn and prevIous treatment with triple-drug therapy (cvclosporine. azathiopnne. and sterOids) and conventional rescue therapy for relechon oi at least two courses of intravenous sterOids and one or more courses' oi antilvmphocvte therapy (antithvmocvte globulin. antllvmphocvte globulin. or OKT3).
The 10 patients In the rescue group represented an extremelv heterogeneous population. Six of them were reierred to our inStitution from other centers. They were younger (age range, 22 to 50 years I and were seen earlier after transplantation (range, 3 to 22 months; average. 8 00034975'92'55.00 ARMITAGE ET Al FK 50fIIN CARDIAC TRANSPlA. .... 'TATION months) than those from our own center. All 6 patients referred for FK 506 rescue had refractory grade 3A or greater rejection and had received at least one course of OKT3 and two courses of intravenous methylprednisolone. Three of the 6 had received both antlthvmocvte globulin and OKT3. One patient had had two course~ of antithymocyte globulin and one course of OKT3. Another patient had had a course of methotrexate. All of these patients were receiving high-dose cyclosporine. azathioprine. and prednisone. 20 to 50 mg/day. One patient had had a panel reactive antibody of 60% before transplantation. had acutely rejected the first transplanted heart. and was supported on extracorporeal membrane oxygenation for a week before retransplantation. She then had persistent rejection of the second heart and was referred for rescue.
The 4 patients from our center (age range. 53 to 67 years) had undergone transplantation 1 year to 4 years previouslv (average time. 2.5 years). All had received one to two courses of antithymocyte globulin and one to two attempts at steroid therapy and had persistent grade 3A relection. Slam" TTlafll'Y \lethvlprednisolone. ;-tll 10 mg'kg. was administered Intravenously in the operatmg roum and in three divided doses ior a total of 5 mg/kg in the iirst 24 hours after transplantation. Therealter. patients received oral prednisone. 0.15 mg • kg -I , day -I, In the early trial (October 1989 to August 1990). steroid weanmg was begun at the llrst week after transplantation based on ireedom from relectlOn. Since August 1990. steroid weaning has begun Jt the 12th posttransplant week. again based on freedom from relection.
F K 506 Therapy

Otlltr A~ellts
Azathiopnne was reserv~ as an adjunctive immunosuppressIVe agent to aid in control of rejection or to allow Ann Thnfil(' Su~ 199"'..;54:~1\ lower FK 506 treatment in patients with renal dvsfunction. OKT3 was reserved for severe rejection ass"aciated with hypotension or hemodynamiC compromise.
All patients entered into the FK 506 immunotherapy protocol were placed on a regimen of prophylactic oral trimethoprimisulfamethoxazole and nystatin (Mycostatin; E.R. SqUibb & Sons, Princeton. NJ). Acvclovir was administered for the first 6 months aiter t~ansplantatlOn and discontinued thereafter.
FK 506 Rescue Therapy
"Rescue" treatment required a 7-to 14-day hospitalization. The medical records and endomyocardial biopsy slides of the patients were reviewed. and complete blood screening as well as chest and abdominal computed tomographic scans were performed. Cyclosporine administration was discontinued the day of admission. and in 8 of the 10 patients. azathioprine was also discontinued. Steroid dose was diminished to half the maintenance dose. No intravenous loading dose of FK 506 was administered. The patients were begun on a regimen oi oral FK 506, 0.3 mg • kg -I • day -I, in two divided doses. and FK 506 levels were targeted at 1 to 1.5 ngimL. Cardiac function was evaluated by multigated acquisition scan and echocardiography before and after FK 506 rescue. An endomyocardial biopsy was performed on day 7. If rejection had resolved by day 7, the patient was discharged and followed· with endomyocardial biopsy. echocardiography. blood work. and measurement of FK 506 levels. If rejection had not resolved at the time of the first biopsy. the patient had a second biopsy on day 14. All rescue patients were discharged home within 14 days.
MOllitvrill~ jor Rl?jcctioll
Surveillance of all pallents after transplantation involved weeklv transvenous l!ndomvocardial biopSIes dunng hospitalization and at slowlv increased intervals alter dischar~e. Biopsy specimens were graded using hematoxylin and eosin staining after light mICroscopy by a pathologist who was blinded to the immunosuppressive protocol of the patient. Biopsy grades were ddined accordmg to the standardized nomenclature ior cardiac relectlon [6). Biupsy specimens that were read bdore the advent oi the standardized nomenclature were retrospectively reviewed and graded according to the new stand.udized method.
MOllitoring jor l"fectivlI
All patIents were followed up bv a specialist in Infectious disease. Titers tor hepatitis B virus. herpeSVirus. EpstelnBarr vIrus. human immunodeficiency virus. T,lxoplasma. and cytomegalovirus were performed on aU donors and reCIpients before transplantation. The diagnosis of infection was made using clinical criteria as previouslv defined by this institution [7] . Complete blood screentng was performed dailv in the hospital and at aU (ollow-up Visits. Questlonnaares to identity untoward side effects ot FK 506 were completed on aU patients throughout tollow-up.
Results
Survival
Sixty-six (92%) of the 72 patients entered into this trial are alive. The perioperative mortality (30 days after transplantation) was 4%. The causes of the 3 early deaths were as follows: secondary to pulmonary hypertensiOn/right heart failure; disseminated aspergillosis; and unknown. The patient with an unknown cause died suddenly on. an exercise CYcle at home; he had had no epIsodes of reJection at fo~r biopsies; permission for postmortem examination was denied.
The late mortalit\· (>30 days after transplantation) was 4%. The first late ·death w~s secondary to low cardiac output (day 54); there was no evidence of rejection. cellular or humoral. or serious coronary artery disease at postmortem examination. The second late death was due to pneumonia. empyema. and colitis (month 6), and the third. to mvocardial infarction and coronary arteriopathy after gratti~g (month 10). No death has been attributed to FK 506 therapy or to acute or refractory cardiac reJection.
Rejection
Rejection was defined as any histological diagnosis of grade 3A or greater. An episode of reJection was defined as one biopsy grade of 3A or greater. irrespecttve of sequential occurrence. Recurrent rejection was defined as a biopsy grade of 3A or greater after treatment and resolution of a prior episode of rejection.
[n the primarv therapy group there were 72 patients. 67 of whom were followed up for 90 days or more. We analyzed this group as a whole and also as two groups based on the FK 506 intravenous induction dose: group I. 0.15 mg·kg-I·day-I (n = 20), and group 2, 0.05 mg' kg-I. dav-I (n = 47).
Of these 67 patients. 33% never had an episode of reJection. and 67% had at least one episode. The mean number ot days to the first episode of reJection was 37 :: 52 (median. i6 days; range, 6 to 237 days). The mean number ot episode~ of rejection per pattent within 90 days was 0.95 :: 1.01 (median number. 1). Recurrent rejection occurred in 27.6% oi the total group. The actuarial freedom from reJection at 90 days was 41 % and at 180 days, :>4% (Table 1) .
The high-dose (0.15 mg' kg -I • day -I) FK 506 induction group \group 1) was analvzed and compared with the low-dose (0.05 mg . actuarial freedom from rejection at 90 days was 40% versus 4IIk, respectively. Statistical analysis failed to reveal any significant difference between the two groups In the va~iables of rejection studied with the exception of the mean number of days to the first episode of rejection (Table 2) .
Twentv-one (3IIk) of the 67 patients had FK 506 as the onlv imritunosuppressi\'e agent. Thirty-mne (58%) were giv~n prednisone (5 to 10 mgldayl. and 28 (42'iC) reqUIred azathioprine. Twenty-one patients (317r) were on a regimen of triple therapy (FK 506. azathiopnne. and prednisone). Only 3 patients (4%) required OKT3 for severe rejection.
Seven of the 10 patients in the rescue group were free from rejection after the FK 506 switch. The other 3 each required one subsequent treatment to resolve rejection: I received a prednisone taper; I. an intravenous dose of methylprednisolone for 3 days; and 1. intravenous methylprednisolone and OKT3. The average length of f~l low-up in this group was 11 months. The average mamtenance dose of FK 506 in the rescue group wa.s 0.12 mg • kg -I • day -I. Eight of the 10 patients remained on a regimen of steroids but at considerablv lower doses; the average prednisone dose was 20 mglday before rescue and 7.5 mglday after rescue. Four patients were treated with azathioprine and FK 506. 3 of whom were also receiving prednisone.
Infectioll
Four major infections were present in 3 patients before cardiac transplantation. One pattent had two infections before transplantation: staphylococcal line sepsis secondarv to an intraaortlc balloon pump and sternal Camiltia os·teomvelitis at the time of removal of a Novacor left ventric~lar assIst device. This same patient hOld pulmonarY emboli and iniarctlOns before placement of the dev"ice but remaanl'd free irom antl'Ctlon alter transplantation With FK 506 as the sole immunosuppressive agent. Amphoterrctn was administered lor :; weeks .liter trJnsplantatIOn. ,lnd the palumt recovered WIthout sequelae. The second patient hOld .J KldlSldla pneumoOlJ durrng intraaortlC balloon pump support. received 8 days of Jntibiotic therapy before transplantation . .lnd rt'covered WIthout iurther miectlon. The third F'Jltent WIth In Inlection before transplantatIon had endocarditis .md line sepsis WIth sterile blood cultures be/ore trolnspl.tntatlon. He also recovered without cllmphcoltlOns.
After transplantation. there were 18 infections in the 67 patients followed up for 90 days or more. There were seven maJor infections (10%) in 5 patients. with two deaths secondarY to infection; one was due to disseminated aspergillosis and one, to a gram-negative pneumonia/empyema with subsequent ClostridiuIII difficilt colitis. One patient had a pulmonary abscess and subsequently had development oi an aortic suture line mvcotic aneurysm. which was diagnosed by magnetic reso'nance imaging and repaired. Another patient had two pneumomas, pneumococcal and pneumocystlc. The seventh major infection was a Proteus and staphylococcal abdominal wound infection after explantation of a Novacor left ventricular assist device. There were 11 (16%) minor infections, six of which were gastrointestinal cytomegalovirus.
In the rescue group, 5 (50%) of the 10 patients had infections before or at the time of the FK 506 switch. Two patients had cytomegalovirus and herpetic infections, 3 had cytomegalovirus alone, and 1 patient had a ruptured aortic suture line Salmoneila mycotic aneurysm. Subsequent to FK 506 rescue, there were three infections: bronchitis, gastritis, and pneumonia.
Cardiac Function and Coronary Arteriopathy
All surviving patients had exceUent cardiac function. In the primary patient group, the average left ventricular ejection fraction measured by gated nuclear scan, echocardiography, or both was 0. Coronary arteriopathy after transplantation was defined as any luminal irregularity or any degree of coronary stenosis. To maXimize the pOSSibility 01 detecting coronary disease transplanted from the donor to the reClpient. any reCipient of a donor heart 40 years or older had coronary angiography before discharge alter the transplant procedure. There were 4 such patients. and all the coronary studies were normal. The average donor age was 33 years (range. 19 to 49 years). At the I-yearfollow-up interval. 35 patients have undergone routine left and right heart catheterization with coronarY angiography. and 4 patients (11 ~) have had posttransplantation coronarY arteriopathv. There was one death due to mvocardial infarction In a patient With detected coron~rv disease at 1 year.
Renal Functioll aud HY1Jerte//slOlI
In the 67 patients followed up for 90 davs or more. the mean creatinine level belore transplantation was 1.3 ngtdl (:: 0.8) and at 3 and 6 months alter transplantation, 1. 9 ngldL (:: 0.7) and 2.2 ng/dL (:: 0.5). respecuvelv. In group 1. With high-dose intravenous Induction. the mean pretransplantation creatinine level was 1.4 ngJdL and at 3 and 6 months after transplantation. 2.3 ngldL. In group 2. With lower dose mtravenous FK 506 induction, the mean pretransplantation creabnine level was 1.3 ngJdL and at 3 and 6 months after the procedure, 1.B ngtdL and 2.1 .-\nn Thorac ~ 1 qq2;~:20s..11 ngidL, respectively. Although there was no Significant difference in serum creatmme level between the two groups. 4 patients required dialvsis in the perioperativ@ period, 3 of whom were in group 1. Peak renal dysfunc_ tion occurred at the first postoperative week with an average serum creatinine level of 2.3 ngldL (:: 1.03). In the rescue group. the switch to FK 506 was very Well tolerated with respect to renal dysfunction. The average serum creatinine level was 1.3 ngldL before rescue and 18 ngidL after rescue. Thirty-six (54%) of the 67 patients had diastolic hypertension necessitating antihypertensive therapy. All 36 patients were treated with a single agent, either enalapril maleate or diltiazem hydrochloride_ In the rescue group, 7 of the 10 patients had hypertension before rescue, and all 7 continued to require treatment while receiving FK 506. However, 2 of the 7 patients were able to control the hypertension with single-drug as opposed to double-drug therapy on a regimen of cyclosporine.
Metabolic Studies a11d Side Effects
There were 20 insulin-dependent diabetics among the 67 patients receiving primary FK 506 therapy after cardiac transplantation. Four of the 20 were insulin dependent before transplantation (2 had juvenile-onset diabetes mellitus), and 3 were non-insulin-dependent diabetics. There were 12 new-onset insulin-dependent diabetic patients (20%) among 60 nondiabetic reCipients. Ten of the 12 with new-onset diabetes were also on a regimen of prednisone (average dose, 7 mgJday).
Continued monitoring of hematological and coagulation indices as well as hepatic function failed to rl'veal any abnormalities at this follow-up interval. Cholesterol and triglyceride levels have been slightly lower than those In cydosponne-treated patients. but not slgnllicantlv so. Five patients have borderline elevated unc aCid levels. Elevated serum potassium levels (K + > 5.0 mEqil). which reqUired treatment With furosemide. were seen in 8 patients. This abnormality in K -excrellon was lOde pendent of renal function and has been observed in other organ recipients treated with FK 506.
Side eifects have been rare despite routme ljuestlonnaires during hospitalizatIOn and during outpatient tollow-up. There have been no seizures. cerebrovascular accidents. or neuropathies secondarY to FK 506. One patient In the pnmary therapy group had a thromboembolic oCCIpital cerebrovascular aCCIdent With aSSOCiated hemorrhage and seizure from which he has recovered with little reSidual deficit. There have been occaSional reports of extremity parestheSia and temperature malsensations. usually associated wuh elevated FK 506 levels. One patient ~ith mild multiple sclerosis expenenced akinetic rr.utism while receiving FK 506, which led to a reduction In the dose. He has smce recovered and returned to work. Muscle aches. mild insomnta. and tremor were also reported. Notably absent in this patient group were complaints oi gingIVal hvperplasla or hirsutism_
Posttranspiantation Lymphoproliferative Disease
Ten months after transplantation. 1 patient (1.4%) in the primary therapy group had development of an inflammatory cervical adenopathy. which on excision biopsy was consistent with posttransplantation Iymphoproliferative disease. Reduction in immunotherapy resulted in resolution of the process. and no recurrence has been detected at 16 months' follow-tlp_ Two months after rescue. 1 patient in the rescue group also had posttransplantation Iymphoproliferative disease. which manifested as gastrointestinal hemorrhage necessitating laparotomy. Again. reduction in immunotherapy led to resolution of the disease process. Her immunosuppression regimen before rescue had consisted of four courses of intravenous steroids and OKT3 with cydosporine. azathioprine. and prednisone over a 2-month period.
Comment
These earlv results with FK 506 as the basis of immunosuppression hold tremendous promise for the future. both as pnmary immunotherapy in cardiac transplantation and as an effective agent for rescue therapy in refractory cardiac rejection. In a prospective. randomized study (8) performed at the University of Pittsburgh comparing rabbit antithymocyte globulin with OKT3 immunoprophylaxis plus cyclosporine-based triple-drug therapy, the OKT3 immunoprophylaxis group had an actuarial freedom from rejection at 90 days after transplantation of 40% with 1.0 episode of rejection per patient. The actuarial freedom from rejection in the FK 506 and low-dose steroid immunotherapy group at 90 days after transplantation in our study was 41% with 0.95 episodes of reJectlon per patient. However. the percentage of recurrent relection was 48% With OKn/cyciosponne versus 28% With FK 506 (p < 0.01. i analysis).
We have been Impressed with the abilitv oi this new agent to attain immunosuppression In cardiac transplant reCIpients comparable with one of the best immunosuppreSSive protocols at the University of Pittsburgh during the last decade. This level of immunosuppression has been achieved without antilymphocyte therapy. without immunoprophylaxis. <lnd with marked reduction in sterOid and azathiopnne requlrements. Twenty-eight (42%) of the 67 patients In this study who were followed for 90 days or more receive no steroids at .111. The average steroid dose tor those adults on a regimen of prednisone IS 8.6 mgldav. The! dramatic abilitv ot FK 506 to reverse cardiac relechon that has bccn rcfracton' to aggressive treatment With (Onvcntlonal immunotherapeutic tools and the rciatlvelv low rate 01 malor (10'l) phoproliferati\'e disease (1.4%) in the cardiac recipient is similar to the incidence (1.8%) observed in the previous decade of c\'closporine-based immunotherapy (9) .
Despite the excellent tolerance of FK 506 by patients and few obser\'ed or reported side effects. renal dysfunction is a price paid when the drug is used as described in this report. \\' e believe that systematic overdosing occurred in patients receiving FK 506 intravenously in the perioperath'e period in our attempt to achieve high early FK 506 levels (group 1). We have changed initial bolus intravenous FK 506 therapy to continuous Infusion and have lowered the initial intravenous dose to a single 24-hour constant infusion dose at 0.05 mg!l<g. with enteral FK 506 begun on the first postoperative day (group 2). Attendant With reduction of the postoperative .i'ntravenous loading dose of FK 506. the median time to first grade 3A rejection was diminished from 34 to 14 days.
We belie\'e that the intravenous induction dose is important to gain appropriate early downregulation of the immune system. Further refinements in our knowledge regarding FK 506 dosage and therapeutic levels. together with the diminished incidence of hypertension. may actually improve the long-term outlook for renal function in cardiac transplant recipients. The incidence of hypertension was 54% in the FK 506 group versus 70% in the 40 cardiac transplant recipients at the University of Pittsburgh before October 1989.
FK 506 does have a negative effect on the beta islet cell. and this is retlected in the 189'0 incidence of new-onset diabetes in the adult population. This diabetogemc effect was enhanced by the necessity for steroid therapy In 10 of these 13 patients.
As cyclosponne had little impact on the manifestation of chromc allograft rejection or coronarv artenopathy. the full impact of FK 506 has yet to be determtned. The i-year incidence of coronary artenopathy was 11 %. Until we improve our understanding oi the mechanisms and immunobiology of this process and are able to target different arms of immune upregulation. posttransplantation coronan' .lrteriopathv Will contmue to occur at a predictable rate and threaten the lon~-term survival of the (ardiac transplant reCIpient.
Cardiac The Pittsburgh group has made many contnbutions over the last 10 years in the held of heart transplantation and. indeed. thoraetc organ replacement in general. I think this careiul study of a new drug that hit with qUite a splash a year or so ago is another indication of the debt that we owe these Investigators. I have a couple of comments and then a couple of questions for Dr Armitage. In 1981 when cyclosponne was introduced with similar fanfare. early results indicated that cyclosporine alone or even combined with prednisone was not an adequate regimen. and regimens using multiple therapy were developed. In 1983. we introduced the triple-therapy concept. which you alluded to with FK. W~ and others found that this is a much bett~r regimen in terms of a lower incidence ot relection and infection and better overall survIval. We have employed this regimen In all subsequent heart. lung. and heart-lung reetplents and conhnue to iind It effecttve.
In light oi these results. why would you propose that we SWItch to FK? We now are observm~ approxlmatelv 80'7r relectlOn-lree surVival at 1 \'~ar. and others uSing tnple therapy have had at It.''3st SO'7, relectlon-Iree survl\'al at 1 veal' and bevond. We have SImIlar rates oi In/echon. and we have never emploved Inducllon or Immunoprophvlaxls as you Indicated you had.
Second. I think an Important concept IS the one you Introduced for reiractorv relectlon. This is an exetting and potentIally verv important area. although I Jm puzzled by the average election fraction ot greater than !l.t>(} in "our reiractorv rejection group. This corresponds to uur e'penence. but nonetheless. this may be In excIting potential appllcatton lur this drug.
Third. the bottum line lor anv 01 thl'~ regimens IS what their Impact wIll be on coronan: artcrv dlsea~. This is sttll the malor long-term Impediment to survIVal. Based on euher m\'eslIgatlOnal or clinical grounds. what are vour Initial impreSSions (oncernlng anv adyantal1;l' 01 this agent over the regImens we use todav?
DR ARMITAGE: I olpprectate vour comments verv much. I would not encourage ~v~ryone to switch immediatelv 10 this drug. It is difficult to make an Impact on the survtval curves that we have nowadays. and th~ survtval curves with this agent are similar to the v~ry good surVIVal curves produced by any other center uSing cyclosponne. No immunosuppressIVe agent IS to be used in a cookbook fasluon. and certallUV with this agent there was a learning curve aSSOCl,lIed WIth its use.
One major advantage tor some of these pahents IS the qualitv of life. mainly in terms ot side effects. Hypertension. although seen. is not so difficult to treat. We have no patients on a regimen of double antihypertenSive therapy. as IS frequently seen With the cyclosponne group. and this may affect long-term renal function. That would be one benefit.
HirsUtism would not be so bad for myself and other gentlemen at my age group. but for a 20-year-old woman. it is a problem. ,md a few of our pediatric patients were switched from cyclesporine for that reason. Hirsutism has not been seen WIth FK 506. nor has gingival hyperplasia. Some of the side effects of the drug are less troublesome. which may have some benefit in terms of quality of life. but it is difficult to have an impact on survival when we are doing so well already. I think the attempt IS to improve the quality of life. and this agent may have some beneilt in that realm.
Regarding coronar\' arterv disease. the inetdence oi coronary Jrteriopathy after transplantation In our FK group IS actuallv a little high. although not outSide the norm. One concern about the drug was that In animal studies. 11 was seen to cause vasculitis in IJrgeanlmals. and part oi the reason that It was nut tned in manv other centers. I think. was the concern that It would produce coronarv vasculitis. We have not seen that or anv other svstemlc. muscular. or central nervous systl'm vasculitis. I think the hope that FK 506 Will diminish or preclude the e"ent 0/ coronarv Jrt~nopathv IS a talse hupe. as It was tor c\'closponne. One or the predictors that Wt.' have sl!t.'n tor the negative l'\1stence ot (oronarv artenopathv IS treatment lor rell'CtIOn. Is it worlhwhile giVing patients a doSt.' ul sterOIds or pulse therapy tI months. 9 months. and 12 months postoperattwlv even II they ha\'e not had an episode oj rl!ll'Ctlon ttl trv and address thiS Issue at Jrtenopathy alter transplantation?
Regarding the rescue group. although ewctlon Iractlons were not diminished In all of the pattents. many 01 them had had episodes 01 diminished erection rractlon. Most had bet.'n able to maintain adequate "entncular lunCtlon With traditional rescue olgents but were unable to clear the cellular response ot relecnon. which was achieved with FK 506. I think that It can be an enect1ve rescue agent. and when 11 is avadable. I think it will be another method by which to treat the problems of the solid-organ transplant rectplent. DR ARMITAGE: There is no question that the drug has nephrotoxicitv. We have learned to ameliorate this a little bv diminishing the intravenous mduction dose, although that ha~ not \'et reached slgmficance. I share your concern about the drug's nephrotoxlCltV. The learning curves aSSOCIated with theuse 01 the drug are verv SimIlar to those ior cvclosponne, and if vou look at the early expenence With c\'c1osponne. similar rises In ereahnine levels and decreases In renal function were seen, Once agaan. the earlv attempts were made to trY to use the drug as a sole agent.
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[ think perhaps that is a mistake and that it can best be used with adjuvant agents.
One thing I did not mention. mainly because this presentation was about adult panents, is that the drug has a major immune advantage in pediatric patients. Its nephrotoxicity appears to be minimal in children. and most children who had heart transplantation with FK 506 immunosuppression are tree Irom nephrotoxicity and from the use of any other agent. I think a very exciting role for this agent IS its use an both heart and lung transplantation in children.
DR COOPER: Is there a significant difference In the creatinine level at 6 months between the FK group and the cyclosponne group with which you compared it?
DR ARMITAGE: When we re\'iewed the cases 01 the 40 patients undergomg transplantallon at our center beiore the advent of FK 506 and treated with cyclosponne, the average creatmine level in that group was about 1.7. It was about 2.1 in the FK group at 6 months. That is not a Significant diffl'rence. However. from the standpoint 01 renal functIOn, patients tolerate cvclosponne as we use It now better than FK 506 as used in this study ..
